Table I.
Clinical course and prognosis of the breast cancer cases depending on the chemotherapy regimen.
| Regimen | No. of patients | No. of patients with recurrence | Relapse-free survival [mean (range) months] | No. of deaths | Overall survival [mean (range) months] |
|---|---|---|---|---|---|
| FEC + docetaxel | 14 | 2 | 32 (8–108) | 1 | 34 (1–114) |
| FEC + paclitaxel | 14 | 5 | 53 (1–114) | 3 | 65 (3–114) |
| FEC + docetaxel + trastuzumab | 5 | 2 | 25 (4–38) | 1 | 27 (5–38) |
| FEC + paclitaxel + trastuzumab | 5 | 2 | 70 (22–96) | 1 | 76 (53–96) |
| FEC | 5 | 1 | 75 (13–106) | 0 | 79 (33–108) |
| CEF | 4 | 2 | 73 (15–104) | 1 | 70 (18–104) |
| FEC + paclitaxel + vinorelbine | 1 | 1 | 3 | 1 | 14 |
| Docetaxel | 1 | 0 | 15 | 0 | 15 |
| Paclitaxel + carboplatin | 1 | 0 | 45 | 0 | 45 |
| Paclitaxel + cisplatin | 1 | 0 | 32 | 1 | 32 |
| Paclitaxel + trastuzumab | 1 | 0 | 22 | 0 | 22 |
FEC, 5-fluorouracil (500 mg/m2, intravenous injection on day 1) -epirubicin (60–100 mg/m2, intravenous injection on day 1) -cyclophosphamide (500 mg/m2, intravenous injection on day 1) / every 3 weeks; CEF, cyclophsphamide (75 mg/m2, internal use on day 1–14) -epirubicin (60 mg/m2, intravenous injection on day 1 and 8) −5-fluorouracil (500 mg/m2, intravenous injection on day 1 and 8) / every 4 weeks.